1H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients

2016 ◽  
Vol 468 (1) ◽  
pp. 168-172 ◽  
Author(s):  
P. E. Menschikov ◽  
N. A. Semenova ◽  
M. V. Ublinskiy ◽  
T. A. Akhadov ◽  
R. A. Keshishyan ◽  
...  
2017 ◽  
Vol 41 (S1) ◽  
pp. S347-S348
Author(s):  
P. Menshchikov ◽  
T. Akhadov ◽  
N. Semenova

IntroductionSome previous findings indicate participation disturbance of balance between excitatory (GABA) and inhibitory (Glu) neurotransmitters in pathogenesis of schizophrenia. The aim of this study was to evaluate GABA and GLX levels in the brain of medicated UHR subjects.ObjectivesTwenty-one (18–25 years, mean = 19.4, SD = 3.5) right-handed medicated UHR men and 26 (18–25 years, mean = 19.8, SD = 2.2) mentally healthy volunteers participated in this study. The patients were included in the UHR group in accordance with criteria of prodromal states.Methods1H MRS (MEGA-PRESS pulse sequence [Mescher, NMR Biomed 1998;11:266]) was used for GABA and GLX detection. Volumes of interest in size of 30 × 30 × 30 mm were placed in the left and right frontal lobes in the areas of the anterior cingulate cortex (ACC) (Fig. 1).ResultsThe main effects on the GABA/Cr (t[45] = 4.17, P < 0.01) (Fig. 2A) and GABA/GLX (t[45] = 2.84, P < 0.01) (Fig. 2B), were found in the left ACC (t[45] = 4.17, P < 0.01), with the patients having lower GABA/Cr and GABA/GLX ratios as compared to the control group. Also significant negative correlation (r = −0.49, P = 0.04) between GABA/Cr in the right ACC and the current daily dosage of antipsychotic medication in CPZ-Eq was found (Fig. 3).ConclusionThis study reveals for the first time a significant reduction of (GABA) (25%) and GABA/GLX ratio (20%) in left AC of UHR subjects. According to (de la Fuente-Sandoval, Int J Neuropsychopharmacol 2015;19[3]) and association of (GABA) with daily dosage of medication found, this reduction may be caused by the antipsichotic treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Author(s):  
Tina D. Kristensen ◽  
Louise B. Glenthøj ◽  
Karen Ambrosen ◽  
Warda Syeda ◽  
Jayachandra M. Ragahava ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e045235
Author(s):  
Felicity Waite ◽  
Thomas Kabir ◽  
Louise Johns ◽  
Jill Mollison ◽  
Apostolos Tsiachristas ◽  
...  

BackgroundEffective interventions, targeting key contributory causal factors, are needed to prevent the emergence of severe mental health problems in young people. Insomnia is a common clinical issue that is problematic in its own right but that also leads to the development and persistence of psychotic experiences. The implication is that treating sleep problems may prevent the onset of psychosis. We collected initial case series data with 12 young people at ultra-high-risk of psychosis. Post-intervention, there were improvements in sleep, depression and psychotic experiences. Now we test the feasibility of a randomised controlled trial, with a clinical aim to treat sleep problems and hence reduce depression, psychotic experiences, and prevent transition to psychosis.Methods and analysisA randomised controlled feasibility trial will be conducted. Forty patients aged 14 to 25 years who are at ultra-high-risk of psychosis and have sleep disturbance will be recruited from National Health Service (NHS) mental health services. Participants will be randomised to receive either a novel, targeted, youth-focussed sleep intervention in addition to usual care or usual care alone. Assessor-blinded assessments will be conducted at baseline, 3 months (post-intervention) and 9 months (follow-up). The eight-session psychological intervention will target the key mechanisms which disrupt sleep: circadian rhythm irregularities, low sleep pressure, and hyperarousal. To gain an in-depth understanding of participants’ views on the acceptability of the intervention and study procedures, 16 participants (n=10 intervention, n=6 control) will take part in qualitative interviews. Analyses will focus on feasibility outcomes (recruitment, retention, and treatment uptake rates) and provide initial CI estimates of intervention effects. Thematic analysis of the qualitative interviews will assess the acceptability of the intervention and trial procedures.Ethics and disseminationThe trial has received ethical approval from the NHS Health Research Authority. Findings will be disseminated through peer-reviewed publications, conference presentations, and lay networks.Trial registration numberISRCTN85601537.


2011 ◽  
Vol 10 (1) ◽  
pp. 26 ◽  
Author(s):  
Shigenori Tadokoro ◽  
Nobuhisa Kanahara ◽  
Shuichi Kikuchi ◽  
Kenji Hashimoto ◽  
Iyo Masaomi

Sign in / Sign up

Export Citation Format

Share Document